<DOC>
	<DOCNO>NCT00031187</DOCNO>
	<brief_summary>SGN-15 investigated therapy patient prostate cancer combination cytotoxic agent , Taxotere . The study open label , randomize phase II study patient document hormone refractory prostate cancer prior therapy Taxotere Novantrone . Both SGN-15 Taxotere administer weekly two 6 week course separate 2 week rest period .</brief_summary>
	<brief_title>Study SGN-15 , Antibody-Drug Conjugate , Treat Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>The purpose study evaluate new class biologic agent , monoclonal antibody ( mAb ) drug conjugate SGN-15 ( cBR96 - Doxorubicin immunoconjugate ) , use combination taxane agent , TAXOTERE ( docetaxel ) strategy target advanced stage , hormone refractory prostate carcinoma ( HRPC ) . This randomized , open label , phase II study evaluate immunoconjugate SGN-15 combination taxane TAXOTERE comparison TAXOTERE alone patient HRPC . Based previous phase I study SGN-15/TAXOTERE combination , weekly dose SGN-15 200 mg/m2 weekly dose TAXOTERE 35 mg/m2 . The schedule administration agent weekly , SGN-15 administer prior TAXOTERE patient treat combination . A single course therapy define 6 weekly dos follow 2 week rest period total 8 week . The study perform interim analysis data 80 patient complete two course . Patients treat minimum 2 course therapy . Additionally , patient remain eligible experienced tolerable level drug toxicity , repeat dose subsequent cycle possible . Patients remove study evidence tumor progression intolerable toxicity . Follow-up assessment include adverse event reporting , clinical laboratory study , quality life ( QOL ) assessment use validated QOL instrument .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>BRIEF : Patients must pathologically confirm prostate cancer , refractory hormone therapy . There must evidence advance disease , determine increase bidimensional unidimensional measurable tumor increase PSA document metastatic disease . Patients must Lewis ( Y ) antigen expression document immunohistochemistry archive fresh tumor specimen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Lewis Blood-Group System</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antigens , Neoplasm</keyword>
	<keyword>Antineoplastic Agents</keyword>
</DOC>